Supplemental Tables from Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer
Year: 2023
Type: supplementary-materials
Abstract: Supplemental Table 1A: Clinical and pathologic characteristics of postmenopausal patients with estrogen receptor-positive breast cancer treated with neoadjuvant aromatase inhibitors at MD Anderson under Z1031 protocol (n = 58) Supplemental Table 1B Biomarkers in the residual tumor Supplemental Table 2: Comparison of Clinical and pathologic characteristics of the MD Anderson cohort and the none-MD Anderson cohort on the Z1031 study. Supplemental Table 3: Ki67, preoperative endocrine prognostic index (PEPI) score, cytoplasmic low molecular weight cyclin E (LMW-E), and cytoplasmic phospho-CDK2 (pCDK2) in postmenopausal patients with estrogen receptor-positive breast cancer treated with neoadjuvant aromatase inhibitors at MD Anderson under Z1031 protocol (n = 58)
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361932175